select a format

Single User License
USD 250 INR 16258
Site License
USD 500 INR 32515
Corporate User License
USD 750 INR 48773

Alternatively

Request a quote
Request a Customized research
Request for Sample Report

NEWSLETTER BY CATEGORY




Recent Viewed Reports


Why Ken Reasearch?


Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"


Zeria Pharmaceutical Co Ltd (4559)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Zeria Pharmaceutical Co Ltd (4559)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH34362D
  • |
  • Pages: 30
  • |
  • May 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

Zeria Pharmaceutical Co Ltd (Zeria), formerly Zeria Yakusho Kenkyusho Co., Ltd. is a pharmaceutical company that manufactures, sells, imports and exports pharmaceuticals and non-pharmaceutical products, veterinary pharmaceuticals, industrial chemicals and reagents, and other products. The company also offers ethical and OTC drugs and products. Its ethical products include therapeutic agent for functional dyspepsia, therapeutic agent for ulcerative colitis, therapeutic agent for gastritis and ulcers, proton pump inhibitor, therapeutic agent for hypophosphatemia, and others. Zeria offers OTC drugs and products such as self-prevention products, remedies for gastrointestinal diseases, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, and hemorroidal remedies, among others. The company markets its products through its branch offices. Zeria is headquartered in Chuo, Japan.

Zeria Pharmaceutical Co Ltd (4559)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Zeria Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Tillotts Pharma Acquires Entocort from AstraZeneca 12

Venture Financing 12

Cancer Prevention Pharma Raises US$0.4 Million In Venture Financing 12

Cancer Prevention Pharma Raises Funds Through Venture Financing 13

Cancer Prevention Pharma Secures US$0.55 Million In Venture Financing 14

Partnerships 15

PendoPharm Enters into Distribution Agreement with Tillotts Pharma 15

Solid Form Solutions Enters Into Co-Promotion Agreement With Tillotts Pharma 15

Cambrex Enters Into Co-Development Agreement With Tillotts Pharma 16

Cancer Prevention Pharma Partners with SWOG 17

Licensing Agreements 18

Sucampo Pharma Enters into Option Agreement with Cancer Prevention Pharma 18

Tillotts Pharma Enters into Licensing Agreement with Numab 18

Eisai Enters into Licensing Agreement with Zeria Pharma for Proton Pump Inhibitor 19

Tillotts Pharma Amends Licensing Agreement with Cancer Prevention Pharma 20

Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 22

Equity Offering 23

Cancer Prevention Pharma Withdraws IPO for up to USD17.5 Million 23

Debt Offering 24

Cancer Prevention Pharma Raises USD2.3 Million in Private Placement of Notes Due 2018 24

Acquisition 25

Zeria Pharma Acquires Remaining 15% Stake In ZPD From Rorvig 25

Zeria Pharmaceutical Co Ltd-Key Competitors 26

Key Employees 27

Locations And Subsidiaries 28

Head Office 28

Other Locations & Subsidiaries 28

Appendix 30

Methodology 30

About GlobalData 30

Contact Us 30

Disclaimer 30

List of Figures

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Zeria Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9

List of Tables

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Zeria Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 8

Zeria Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 9

Zeria Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Tillotts Pharma Acquires Entocort from AstraZeneca 12

Cancer Prevention Pharma Raises US$0.4 Million In Venture Financing 12

Cancer Prevention Pharma Raises Funds Through Venture Financing 13

Cancer Prevention Pharma Secures US$0.55 Million In Venture Financing 14

PendoPharm Enters into Distribution Agreement with Tillotts Pharma 15

Solid Form Solutions Enters Into Co-Promotion Agreement With Tillotts Pharma 15

Cambrex Enters Into Co-Development Agreement With Tillotts Pharma 16

Cancer Prevention Pharma Partners with SWOG 17

Sucampo Pharma Enters into Option Agreement with Cancer Prevention Pharma 18

Tillotts Pharma Enters into Licensing Agreement with Numab 18

Eisai Enters into Licensing Agreement with Zeria Pharma for Proton Pump Inhibitor 19

Tillotts Pharma Amends Licensing Agreement with Cancer Prevention Pharma 20

Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 22

Cancer Prevention Pharma Withdraws IPO for up to USD17.5 Million 23

Cancer Prevention Pharma Raises USD2.3 Million in Private Placement of Notes Due 2018 24

Zeria Pharma Acquires Remaining 15% Stake In ZPD From Rorvig 25

Zeria Pharmaceutical Co Ltd, Key Competitors 26

Zeria Pharmaceutical Co Ltd, Key Employees 27

Zeria Pharmaceutical Co Ltd, Other Locations 28

Zeria Pharmaceutical Co Ltd, Subsidiaries 29

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Zeria Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com